
Editor-in-Chief: Prof. Giovanni Martinotti, Università degli Studi G. D'Annunzio, Italy; University of Hertfordshire, UK.
Clinical Neuropsychopharmacology and Addiction (CNA) is a peer-reviewed, gold open-access journal committed to advancing the science and practice of neuropsychopharmacology and addiction medicine. CNA aims to publish high-quality, cutting-edge research that explores the psychopharmacological treatment of neuropsychiatric disorders, substance use disorders, and behavioral addictions, fostering innovation and interdisciplinary collaboration in these critical areas. It is published quarterly online by Scilight Press. More
The Dopaminergic Coup d’État: Neurobiology of Addiction and the Architecture of Desire
Claudia Anna Filloramo, Luigi Dattoli
2026, 2(3): 11. doi: 10.53941/cna.2026.100011
Occupational stress, Glossophobia, and Impostor Cognitions: An Integrative Clinical Case Study of Anxiety and Maladaptive Psychotropic Coping
Laila ESSFIOUI
2026, 2(2): 10. doi: 10.53941/cna.2026.100010
Sex- and Age-Stratified Differences in Antidepressant Response to Intranasal Esketamine in Treatment-Resistant Depression: A Secondary Analysis of the REAL-ESK Study
Giacomo d'Andrea, Luca Persico, Clara Cavallotto, Serena Panichella, Alessia Santeusanio, Alessandra Di Tullio, Michela D'Angola, Arianna Rosati, Antonio Inserra, Gianfranco Tamagnini, Cristina Di Puorto, Virginio Salvi, Beniamino Tripodi, Domenico De Berardis, Vassilis Martiadis, Milena Piccirillo, Fabiola Raffone, Tommaso Vannucchi, Andrea Barra, Matteo Lupi, Livia Miotti, Andrea Di Cesare, Mauro Pettorruso
2026, 2(2): 9. doi: 10.53941/cna.2026.100009
The Role of Probiotic Supplementation in Alcohol-Seeking Behavior: Behavioral and Neurochemical Correlates
Huma Ikram, Shahla Perveen, Darakhshan J. Haleem
2026, 2(2): 8. doi: 10.53941/cna.2026.100008

Deaths Involving Gabapentin and Pregabalin, Scotland, 2000–2024: A Descriptive Account
John Martin Corkery, Amira Guirguis, Fabrizio Schifano
2026, 2(2): 7. doi: 10.53941/cna.2026.100007
Epigenetic Mechanisms of Psychedelics in Addiction: Emerging Evidence and Therapeutic Potential
Antonio Inserra, Francesca Zoratto, Mauro Pettorruso, Giovanni Martinotti
2026, 2(2): 6. doi: 10.53941/cna.2026.100006

Can Substance-Induced Psychoses (SIP) Shed Light on the Paradigm of Schizophrenia?
Alessio Mosca, Filippo Maria Ferro
2026, 2(1): 5. doi: 10.53941/cna.2026.100005
Aripiprazole Long Acting and Clozapine: Between Efficacy and Tolerability
Luca Persico, Ludovica Di Sante, Michele Xynelis, Andrea Miuli, Alessio Mosca, Mauro Pettorruso
2026, 2(1): 4. doi: 10.53941/cna.2026.100004
Brexpiprazole in the Management of Schizophrenia and Comorbid Substance Use Disorders: A Narrative Review of Efficacy, Safety, and Real-World Evidence (2020–2026)
Miriam Olivola, Nicolaja Girone, Andrea Crippa, Monica Macellaro, Vassilis Martiadis, Fabiola Raffone, Tiziano Prodi, Natascia Brondino, Roberta Anniverno, Bernardo Dell’Osso
2026, 2(1): 3. doi: 10.53941/cna.2026.100003

Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study
Linério Ribeiro de Novais Júnior, Larissa Mendes da Silva, Vicente Meneguzzo, Suelen de Souza Ramos, Lara Rodrigues da Rosa, Tiago Odilio de Souza, João Victor Simão, Alisson Reuel da Silva, Josiel Mack, Kelser de Souza Kock, Mariana Pereira de Souza Goldim, Antonio Inserra, Rafael Mariano de Bitencourt
2026, 2(1): 2. doi: 10.53941/cna.2026.100002